Search Results - "Tkaczuk, KH"

Update on taxane development: new analogs and new formulations by Yared, Jean A, Tkaczuk, Katherine H R

“…The taxanes (paclitaxel and docetaxel) represent an important class of antineoplastic agents that interfere with microtubule function leading to altered…”
Get full text

Improved Outcomes From Adding Sequential Paclitaxel but Not From Escalating Doxorubicin Dose in an Adjuvant Chemotherapy Regimen for Patients With Node-Positive Primary Breast Cancer by HENDERSON, I. Craig, BERRY, Donald A, FLEMING, Gini, HOLLAND, James F, DUGGAN, David B, CARPENTER, John T, FREI, Emil III, SCHILSKY, Richard L, WOOD, William C, MUSS, Hyman B, NORTON, Larry, DEMETRI, George D, CIRRINCIONE, Constance T, GOLDSTEIN, Lori J, MARTINO, Silvana, INGLE, James N, COOPER, M. Robert, HAYES, Daniel F, TKACZUK, Katherine H

“…This study was designed to determine whether increasing the dose of doxorubicin in or adding paclitaxel to a standard adjuvant chemotherapy regimen for breast…”
Get full text

Abstract P1-12-01: A phase II, open-label, multi-center study of ANG1005, a novel brain-penetrant peptide-drug conjugate, in breast cancer patients with recurrent CNS metastases by Ibrahim, NK, Tang, S-C, Brenner, AJ, Kesari, S, Piccioni, DE, Anders, CK, Carillo, JA, Chalasani, P, Kabos, P, Puhalla, S, Garcia, AA, Tkaczuk, KH, Ahluwalia, MS, Lakhani, NJ, Kumthekar, P

“…Abstract Background: The incidence of CNS metastatic disease in breast cancer patients (pts) seems to have increased in recent years with the improvement of…”
Get full text

Abstract P5-15-08: Clinical factors that contribute to choice of mastectomy in patients eligible for breast conservation therapy by Reese, AS, Kesmodel, SB, Bellavance, EC, Reese, JB, Campassi, C, Tkaczuk, KH, Bao, T, Chumsri, SS, Olson, JA, Feigenberg, SJ

“…Abstract Purpose/Objective(s): To evaluate clinical factors associated with the choice of mastectomy in patients eligible for breast conservation therapy (BCT)…”
Get full text

Body mass and stage of breast cancer at diagnosis by Cui, Yadong, Whiteman, Maura K., Flaws, Jodi A., Langenberg, Patricia, Tkaczuk, Katherine H., Bush, Trudy L.

“…Obesity is a well‐known risk factor for postmenopausal breast cancer. In contrast, the relationship between obesity and stage of breast cancer at diagnosis is…”
Get full text

Social support as a buffer to the psychological impact of stressful life events in women with breast cancer by Kornblith, Alice B., Herndon, James E., Zuckerman, Enid, Viscoli, Catherine M., Horwitz, Ralph I., Cooper, M. Robert, Harris, Lyndsay, Tkaczuk, Katherine H., Perry, Michael C., Budman, Daniel, Norton, Larry, Holland, Jimmie C.

“…BACKGROUND Three theoretical models by which social support may influence the impact of stressful life events on cancer patients' psychological state were…”
Get full text

Pharmacokinetics of doxorubicin administered i.v. as Myocet (TLC D-99; liposome-encapsulated doxorubicin citrate) compared with conventional doxorubicin when given in combination with cyclophosphamide in patients with metastatic breast cancer by Swenson, Christine E, Bolcsak, Lois E, Batist, Gerald, Guthrie, Troy H, Tkaczuk, Katherine H, Boxenbaum, Harold, Welles, Lauri, Chow, Shein-Chung, Bhamra, Rupinder, Chaikin, Philip

“…Myocet (TLC D-99) is a liposomal formulation of the anti-neoplastic drug doxorubicin with an improved therapeutic index compared with conventional doxorubicin…”
Get full text

Suramin, an active drug for prostate cancer: interim observations in a phase I trial by Eisenberger, M A, Reyno, L M, Jodrell, D I, Sinibaldi, V J, Tkaczuk, K H, Sridhara, R, Zuhowski, E G, Lowitt, M H, Jacobs, S C, Egorin, M J

“…Previous studies indicate that suramin may be an active agent for treatment of solid tumors. The clinical use of suramin is complicated by a broad spectrum of…”
Get more information

Phase I and clinical evaluation of a pharmacologically guided regimen of suramin in patients with hormone-refractory prostate cancer by Eisenberger, M A, Sinibaldi, V J, Reyno, L M, Sridhara, R, Jodrell, D I, Zuhowski, E G, Tkaczuk, K H, Lowitt, M H, Hemady, R K, Jacobs, S C

“…This phase I study was designed with the following objectives: (1) to describe the overall and dose-limiting toxicity (DLT) of suramin administered by…”
Get more information

Pharmacokinetic and Pharmacodynamic Study of the Combination of Docetaxel and Topotecan in Patients With Solid Tumors by ZAMBONI, William C, EGORIN, Merrill J, TKACZUK, Katherine H, VAN ECHO, David A, DAY, Roger S, MEISENBERG, Barry R, BROOKS, Sandra E, DOYLE, L. Austin, NEMIEBOKA, Noble N, DOBSON, Jason M, TAIT, Nancy S

“…The sequence in which chemotherapeutic agents are administered can alter their pharmacokinetics, therapeutic effect, and toxicity. We evaluated the…”
Get full text

A phase I study of paclitaxel, UFT, and leucovorin by Gojo, I, Tkaczuk, K H

“…This phase I study examines the dose escalation of UFT given in combination with fixed doses of oral leucovorin and weekly doses of paclitaxel in patients with…”
Get more information

Suramin: development of a population pharmacokinetic model and its use with intermittent short infusions to control plasma drug concentration in patients with prostate cancer by Jodrell, D I, Reyno, L M, Sridhara, R, Eisenberger, M A, Tkaczuk, K H, Zuhowski, E G, Sinibaldi, V J, Novak, M J, Egorin, M J

“…This study aimed to (1) develop a population pharmacokinetic model for suramin; (2) use Bayesian methods to assess suramin pharmacokinetics in individual…”
Get more information

Phase I study of docetaxel and topotecan in patients with solid tumors by TKACZUK, Katherine H, ZAMBONI, William C, TAIT, Nancy S, MEISENBERG, Barry R, DOYLE, L. Austin, EDELMAN, Martin J, HAUSNER, Petr F, EGORIN, Merrill J, VAN ECHO, David A

“…Both docetaxel (DOC), a promoter and stabilizer of microtubule assembly, and topotecan (TOPO), a topoisomerase I inhibitor, have shown antitumor activity in a…”
Get full text

Can obesity explain the racial difference in stage of breast cancer at diagnosis between black and white women? by Cui, Yadong, Whiteman, Maura K, Langenberg, Patricia, Sexton, Mary, Tkaczuk, Katherine H, Flaws, Jodi A, Bush, Trudy L

“…Black women are more likely to be diagnosed at a more advanced stage of breast cancer than are white women. Traditionally, this has been attributed in part to…”
Get more information